{"entity":{"id":"idea-data-outcome-based-price-reassessment","kind":"idea","name":"Reassess cancer drug prices at three years using real-world outcomes","aka":[],"tldr":"Set the price of a new cancer drug provisionally, then adjust it up or down after three years depending on how well patients actually did.","summary":"Prices are set at approval on trial data and rarely revisited. Outcome-based agreements exist but are bespoke and opaque. The proposal is a standard pricing rule: initial price tied to trial evidence, mandatory structured outcome capture, and a scheduled reassessment at three years using pre-specified real-world survival and toxicity metrics, with published adjustment formulae. Italy's AIFA registries and Germany's AMNOG reassessments are partial precedents.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Weak real-world evidence and registries): Gyawali, Hey & Kesselheim, Assessment of the clinical benefit of cancer drugs receiving accelerated approval (JAMA Intern Med 2019)","url":"https://doi.org/10.1001/jamainternmed.2019.0462"}],"tags":[],"related":["idea-data-coverage-with-evidence-development"],"cancers":[],"sections":["ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":[],"bottlenecks":["b-real-world-evidence","b-drug-pricing","b-incentive-misalignment"],"keyPapers":["paper-gyawali-jama-intern-med"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Scheduled reassessment will lower prices for drugs whose real-world benefit falls short of trial results and will make outcome capture near-complete because payment depends on it.","rationale":"Payment tied to data has been the only reliable driver of completeness (see SACT); tying price to outcome aligns the incentive to collect with the incentive to deliver value.","test":"Apply the rule to ten new indications in one national payer; report data completeness and the direction and size of price adjustments at reassessment.","maturity":"early-clinical","actor":"payer","cost":"medium","horizonYears":4},"route":"/ideas/idea-data-outcome-based-price-reassessment/","neighbours":{"idea":[{"id":"idea-data-coverage-with-evidence-development","kind":"idea","name":"Payers fund cancer drugs conditionally on a registry with a pre-specified analysis","route":"/ideas/idea-data-coverage-with-evidence-development/"}],"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"}],"term":[{"id":"real-world-evidence","kind":"term","name":"Real-world evidence","route":"/terms/real-world-evidence/"}],"bottleneck":[{"id":"b-incentive-misalignment","kind":"bottleneck","name":"Incentives reward me-too drugs and marginal gains","route":"/bottlenecks/b-incentive-misalignment/"},{"id":"b-drug-pricing","kind":"bottleneck","name":"Prices and value","route":"/bottlenecks/b-drug-pricing/"},{"id":"b-real-world-evidence","kind":"bottleneck","name":"Weak real-world evidence and registries","route":"/bottlenecks/b-real-world-evidence/"}],"paper":[{"id":"paper-gyawali-jama-intern-med","kind":"paper","name":"Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval","route":"/key-papers/paper-gyawali-jama-intern-med/"}]}}